Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711
Recruiting
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/09/2025
Locations: UCONN Health, Farmington, Connecticut
Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Register for Updates
Effects of Repeated Psilocybin Dosing in OCD
NCT05370911
Recruiting
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/09/2025
Locations: Yale OCD Research Clinic (40 Temple St, 4th Floor), New Haven, Connecticut
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449
Recruiting
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Register for Updates
Imaging Depression in Parkinson's Disease
NCT06402955
Recruiting
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Parkinson's Disease, Major Depressive Disorder
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation
NCT06407427
Recruiting
This study aims to evaluate the effectiveness of a mobile application in improving postoperative rehabilitation outcomes among patients undergoing orthopedic surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale New Haven Hospital Saint Raphael's Campus, New Haven, Connecticut
Conditions: Spine Degeneration, Hip Arthritis, Knee Osteoarthritis, Hip Fractures
Register for Updates
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762
Recruiting
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Yale Universtiy, New Haven, Connecticut
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
NCT06521762
Recruiting
This is a randomized, double-blind, placebo-controlled, two-arm phase 2 study of etrasimod plus corticosteroids versus placebo plus corticosteroids for the treatment of IMDC CTCAE v5.0 grade ≥ 2 due to ICI therapy alone (α-PD-(L)1 monotherapy or combined with another ICI, such as α-CTLA-4 or α-LAG-3) or ICI plus an oral tyrosine kinase inhibitor that in the opinion of the treating physician requires treatment with corticosteroid-based immunosuppression and does not require immediate secondary im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/07/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
NCT06371404
Recruiting
The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/07/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder, Post Traumatic Stress Disorder
Register for Updates
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Metastatic Prostate Cancer
Register for Updates